Regeneron Pharmaceuticals, Inc.
REGNBiotechnologyOpen
810.25+0.3%Up to 800x leverageTrade REGN
What it reported
Reported 89 days ago, on 2026-07-30.
Forecast against the result
| Forecast | Reported | Surprise | |
|---|---|---|---|
| Revenue | 3.8B | 4.3B+16.7% year on year | +12.4% |
| Net income | 1.1B | 1.3B-6.8% year on year | +19.6% |
| Earnings per share | 10.16 | 14.29+10.9% year on year | +40.6% |
Year on year compares the same quarter a year earlier (2025-08-01), not the quarter before.
REGN trades at up to 800x here. At 800x, a 0.13% move against you wipes out the whole margin. This ignores fees, funding and maintenance margin, all of which bring liquidation forward. Your actual liquidation price is the one shown on the order page.
You can hold through the announcement here
REGN is quoted here 24 hours a day and does not stop when the US market closes. On a US exchange the same news only shows up as a gap at the next open.
What the market expects
For the quarter ending 2026-09-30.
Against the same quarter last year (2025-10-28): EPS +38.3%revenue +21.5%
These are third-party analyst forecasts. CoinUnited.io does not produce them and does not choose which analysts are included.
Where the revenue comes from
- Collaboration Revenue57.2%2.5B
- Product38.3%1.6B
- Product and Service, Other4.5%193.3M
Most recent reported quarter (2026-06-30).
Track record
Next report expected 2026-10-30. Reports quarterly.
Beat estimates 7 of the last 8 quarters. The typical gap is +0.81 per share.
How much it actually moves
±6.2%
Median move across the two sessions around the report, over its last 8 results. On an ordinary two-day stretch it moves 1.5%.
2026-07-30+14.34%
2024-10-31Move over the two sessions around each report2026-07-30
Beat or miss, then up or down
| Rose | Fell | |
|---|---|---|
| Beat | 5 | 2 |
| Missed | 0 | 1 |
Counted across 8 results. This is what happened, not what will.
Where analysts put it in 12 months
A different timescale from the rest of this page: these are 12-month views, not the two-day move around a report.
| Firm | Target | Set on | Source |
|---|---|---|---|
| Piper Sandler | 865.00 | 2026-10-19 | TheFly |
| UBS | 978.00 | 2026-10-14 | TheFly |
| RBC Capital | 810.00 | 2026-10-08 | TheFly |
| Raymond James | 911.00 | 2026-10-08 | StreetInsider |
| Truist Financial | 780.00 | 2026-10-07 | TheFly |
| Morgan Stanley | 779.00 | 2026-10-07 | TheFly |
| Jefferies | 930.00 | 2026-10-01 | TheFly |
| BMO Capital | 920.00 | 2026-10-01 | StreetInsider |
| Argus Research | 850.00 | 2026-10-01 | TheFly |
| HSBC | 920.00 | 2026-09-10 | TheFly |
| Leerink Partners | 824.00 | 2026-08-17 | TheFly |
| Bernstein | 756.00 | 2026-08-14 | StreetInsider |
| Guggenheim | 1030.00 | 2026-08-03 | TheFly |
| Cantor Fitzgerald | 795.00 | 2026-07-31 | TheFly |
| Robert W. Baird | 761.00 | 2026-07-31 | TheFly |
From 20 firms that published a target in the last 180 days, latest call per firm. Targets are set by those firms; CoinUnited.io does not produce or endorse them.
Reported results
| Reported | EPS forecast | EPS actual | Surprise | Revenue surprise |
|---|---|---|---|---|
| 2026-07-30 | 10.16 | 14.29 | +40.6% | +12.4% |
| 2026-04-29 | 8.91 | 9.47 | +6.3% | +3.6% |
| 2026-01-30 | 10.74 | 11.44 | +6.5% | +1.9% |
| 2025-10-28 | 9.65 | 11.83 | +22.6% | +4.5% |
| 2025-08-01 | 8.43 | 12.89 | +52.9% | +11.8% |
| 2025-04-29 | 8.62 | 8.22 | -4.6% | -6.8% |
| 2025-02-04 | 11.21 | 12.07 | +7.7% | +1.3% |
| 2024-10-31 | 11.69 | 12.46 | +6.6% | +1.2% |
| 2024-08-01 | 10.61 | 11.56 | +9.0% | +4.8% |
| 2024-05-02 | 10.17 | 9.55 | -6.1% | -2.5% |
| 2024-02-02 | 10.73 | 11.86 | +10.5% | +4.2% |
| 2023-11-02 | 10.72 | 11.59 | +8.1% | +4.4% |
Also reporting this fortnight in Biotechnology
ALNY 
INSM 
MRNA 
ROIV 
RVMD 
TECH 2 more in Biotechnology
EPS history for REGN runs from 1990-03-31 to 2026-07-30, 128 reports.Reaction history covers its last 8 results, which is as deep as our daily price baseline reaches.